Waypoint Bio Raises $20M Series A
2026-06-01
Tweet
NEW YORK,NY, Waypoint Bio, an AI-native biotech company using spatial biology to design next-generation CAR T therapies for solid tumors, announced today that it closed a $20 million Series A financing round.
The financing was led by Amplify Partners and Elliot Hershberg will join the board of directors. General Catalyst, Time BioVentures, Mitsui Global Investments, and Lux Capital participated in the round, alongside existing investors including Hummingbird Ventures.
Waypoint Bio is developing AI-designed therapeutics using a platform that integrates artificial intelligence, computer vision, and spatial pooled screening. The company's lead program is an in vivo CAR T asset paired with a proprietary next-generation lentiviral vector, with clinical entry in China expected in late 2026. Waypoint is based in New York and is extending its platform into biologics and additional therapeutic areas.
Waypoint Bio is developing AI-designed therapeutics using a platform that integrates artificial intelligence, computer vision, and spatial pooled screening. The company's lead program is an in vivo CAR T asset paired with a proprietary next-generation lentiviral vector, with clinical entry in China expected in late 2026. Waypoint is based in New York and is extending its platform into biologics and additional therapeutic areas.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
